SCHEMBL2684575

SCHEMBL2684575

CNc1c(OC)cccc1C(=O)OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.53
POLB P06746 2/20 0.53
ATM Q13315 1/20 0.53
GAA P10253 3/20 0.51
HSD17B10 Q99714 3/20 0.51
MAPT P10636 3/20 0.51
TSHR P16473 2/20 0.51
MAPK1 P28482 1/20 0.51
ALDH1A1 P00352 3/20 0.48
SLC6A3 Q01959 1/20 0.47
LMNA P02545 1/20 0.47
CTSD P07339 1/20 0.46
CFTR P13569 1/20 0.46
KCNK3 O14649 1/20 0.45
KCNK9 Q9NPC2 1/20 0.45
HPGD P15428 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29453820 1.00 KDM4E (0.53) KDM4EPOLBATMGAAHSD17B10
SCHEMBL31031193 0.86 HTT (0.54) KDM4EHSD17B10TSHRMAPK1ALDH1A1
SCHEMBL12861288 0.86 KCNK3 (0.49) POLBGAAMAPTMAPK1LMNA
SCHEMBL16599381 0.80 POLB (0.55) KDM4EPOLBATMHSD17B10MAPT
SCHEMBL8203446 0.80 LMNA (0.63) KDM4EPOLBATMGAAHSD17B10
SCHEMBL27597208 0.80 KDM4E (0.55) KDM4EPOLBATMHSD17B10MAPT
SCHEMBL18315876 0.79 TSHR (0.56) KDM4EPOLBATMGAAHSD17B10
SCHEMBL30605528 0.79 MAPT (0.46) KDM4EPOLBGAAHSD17B10MAPT
Methyl 2-Methoxybenzoate SCHEMBL196037 0.79 TSHR (0.69) KDM4EPOLBATMGAAHSD17B10
Methyl 2-Methoxybenzoate SCHEMBL29702077 0.79 TSHR (0.69) KDM4EPOLBATMGAAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12161747-B2 Gum and tooth treatment method with rinsing IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-12-10 US disclosed
US-20240390446-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES ALKALAY RACHEL (IL) 2024-11-28 US disclosed
US-20240358626-A1 GUM AND TOOTH TREATMENT METHOD WITH RINSING IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-10-31 US disclosed
US-12102708-B2 Treatment method for teeth and gums IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-10-01 US disclosed
US-20240225996-A1 TREATMENT METHOD FOR TEETH AND GUMS IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-07-11 US disclosed
US-20240226218-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION Novel Concepts Medical Ltd (IL) 2024-07-11 US disclosed
US-12011496-B2 Topical macqui berry formulation Tracie Martyn International, Inc. (US) 2024-06-18 US disclosed
US-11957782-B2 Treatment method for teeth and gums IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-04-16 US disclosed
US-20230346866-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NON-MALIGNANT RESPIRATORY DISEASE Novel Concepts Medical Ltd (IL) 2023-11-02 US disclosed
US-20230346687-A1 FLURIDE RELEASING TOOTHPASTE WITH ANTIBACTERIA AND BIOACTIVE PROPERTIES IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-11-02 US disclosed
CN-103288826-A Alkaloid component in Nigella glandulifera Freyn seeds as well as preparation method and use thereof XINJIANG TECH INST PHYSICS CAS 2013-09-11 CN disclosed
CN-103285000-A Use of alkaloid with framework types I and II in Nigella glandulifera Freyn seeds XINJIANG TECH INST PHYSICS CAS 2013-09-11 CN disclosed
CN-103102305-A Alkaloid of skeleton type 2 in nigella glandulifera preyn and preparation method of alkaloid XINJIANG TECH INST PHYSICS CAS 2013-05-15 CN disclosed
CN-103086967-A Alkaloid having type 1 skeleton in Nigellaglandulifera Freyn grass seeds, and its preparation method XINJIANG TECH INST PHYSICS CAS 2013-05-08 CN disclosed
US-20120114719-A1 Topical Macqui Berry Formulation TRACIE MARTYN INTERNATIONAL, LLC (US) 2012-05-10 US disclosed
US-20100272790-A1 Methods of Treating Skin TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-10-28 US disclosed
US-7776915-B2 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-08-17 US disclosed
US-20070065396-A1 Topical macqui berry formulation TRACIE MARTYN INTERNATIONAL, LLC 2007-03-22 US disclosed
US-20060216251-A1 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2006-09-28 US disclosed
CN-1784411-A Fragrance compositions comprising benzo[4,5]thieno[3,2-b]pyran-2-one FLEXITRAL INC (US) 2006-06-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100272790-A1 Methods of Treating Skin CUTA, LIPA, DLAT KDM4E 1602/4885POLB 1760/4885ATM 3020/4885
US-20240390446-A1 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY DISEASES INCLUDING DIABETES AND THYROID DISEASES TPO, TNF, ADAMTS13 KDM4E 4684/4885POLB 4693/4885ATM 3256/4885
US-20060216251-A1 Topical formulations and methods of use CPT1B, SLC25A20, CPT1A KDM4E 2265/4885POLB 1930/4885ATM 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.